Skip to main content

Table 1 Information about the study subjects

From: ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain

Diagnosis Gender Age Braak stage pm delay (min) CSF pH Brain weight (g)
control F 69 1 375 6.59 1264
control F 72 1 405 6.52 1296
control M 79 1 320 6.72 1322
control M 83 1 275 6.49 1422
control F 88 2 340 n.d. 1152
Control mean 3F/2 M 78.2 1.2 343 6.58 1291
AD F 84 4 230 6.64 1196
AD F 85 4 220 6.59 1065
AD F 93 4 335 6.65 1194
AD F 84 4 230 6.64 1196
AD F 87 4 240 6.91 955
AD F 101 4 265 6.93 1016
AD M 91 4 250 n.d. 1160
AD/LBV F 81 4 193 6.54 1096
AD/LBV F 76 4 295 6.78 1180
AD M 67 5 260 6.62 1094
AD F 77 5 252 6.43 1151
AD F 77 5 215 6.67 1235
AD M 86 5 335 6.39 1315
AD M 95 5 185 6.4 1203
AD M 70 5 525 6.25 1220
AD/LBV M 80 5 1670 6.19 1170
AD/LBV F 69 5 295 6.59 1039
AD/LBV F 84 5 365 6.1 1116
AD/LBV F 87 5 260 6.17 1022
AD/LBV M 84 5 275 6.54 1373
AD M 58 6 385 6.42 1273
AD F 87 6 300 6.66 852
AD F 87 6 250 6.9 1047
AD F 77 6 285 6.74 1116
AD F 91 6 275 6.55 949
AD F 66 6 215 6.42 1105
AD/LBV M 54 6 610 6.51 1334
AD/LBV F 69 6 295 6.41 1003
AD mean 19 F/9 M 80.3 5 340 6.54 1131
  1. There were no statistically significant differences in age, cerebrospinal fluid (CSF) pH or pm delay between AD patients (Braak stages 4, 5 and 6) and controls (Braak stage 1 and 2). Brain weight was significantly lower in the AD patients, compared to controls (p = 0.01, unpaired t-test).